Go/no-go decision for early asset

The challenge

With several other in-class competitors, a client sought Putnam’s guidance on a go/no-go development decision for a first-generation targeted therapy in Phase 1 clinical development.

Our solution

We worked to understand its projected value proposition and commercial viability by assessing the competitive landscape and development approaches, prioritizing opportunities, developing target profiles and value propositions, validating with KOLs, and using base- and best-case assumptions.

The results

We provided the revenue potential of the asset by scenario for visibility on what revenue gaps the asset could fill over a period of time, leading to the client’s go/no-go decision for the early asset.